-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Overweight on Capricor Therapeutics, Raises Price Target to $58

Benzinga·03/13/2026 16:28:56
Listen to the news
Piper Sandler analyst Edward Tenthoff reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Overweight and raises the price target from $45 to $58.